Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.56 |
| ▸ | GPR52 | Q9Y2T5 | 2/20 | 0.56 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 9/20 | 0.51 |
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL960760 | 0.89 | GPR52 (0.53) | GPR52MAP4K4 | |
| SCHEMBL961206 | 0.88 | GPR52 (0.63) | GPR52CYP2C19 | |
| SCHEMBL959859 | 0.87 | GPR52 (0.73) | GPR52MAP4K4 | |
| SCHEMBL3402485 | 0.86 | GPR52 (0.61) | GPR52CYP2C9 | |
| SCHEMBL12918938 | 0.86 | GPR52 (0.61) | GPR52 | |
| Hydrochloric Acid SCHEMBL958163 | 0.85 | GPR52 (0.60) | GPR52 | |
| SCHEMBL959095 | 0.84 | GPR52 (0.59) | GPR52 | |
| SCHEMBL12918981 | 0.84 | SMYD2 (0.56) | SMYD2CACNA1GMAP4K4CYP2C9CYP2C19 | |
| SCHEMBL958255 | 0.83 | GPR52 (0.56) | GPR52MAP4K4 | |
| SCHEMBL12918937 | 0.82 | GPR52 (0.59) | SMYD2GPR52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009421-A1 | COMPOUND HAVING 6-MEMBERED AROMATIC RING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20110009421-A1 | COMPOUND HAVING 6-MEMBERED AROMATIC RING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20110009421-A1 | COMPOUND HAVING 6-MEMBERED AROMATIC RING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2253618-A1 | COMPOUND HAVING 6-MEMBERED AROMATIC RING | Takeda Pharmaceutical Company Limited (JP) | 2010-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009421-A1 | COMPOUND HAVING 6-MEMBERED AROMATIC RING | GPR4, NR3C2, NR5A2 | SMYD2 2582/4885GPR52 23/4885CACNA1G 1425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.